SOLICITATION NOTICE
A -- Controlled Dose-Escalation Trial of Intraparenchymally Infused Recombinant Methionyl Human Glial Cell Line-Derived Neurotrophic Factor for the Treatment of Progressive Supranuclear Palsy
- Notice Date
- 4/24/2002
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute of Neurological Disorders and Stroke, 6001 Executive Boulevard, Neuroscience Center, Suite 3287, MSC 9531, Bethesda, MD, 20892-9531
- ZIP Code
- 20892-9531
- Solicitation Number
- NIH-NINDS-02-12
- Response Due
- 6/8/2002
- Archive Date
- 6/23/2002
- Point of Contact
- Helene Braun, Contract Specialist, Phone 301 496-1813, Fax 301 402-4225, - Helene Braun, Contract Specialist, Phone 301 496-1813, Fax 301 402-4225,
- E-Mail Address
-
braunh@ninds.nih.gov, braunh@ninds.nih.gov
- Description
- The National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health, intends to negotiate a contract with Vanderbilt University Medical Center, Nashville, Tennessee, on a sole source basis for the completion of a protocol entitled, ?Controlled Dose-Escalation Trial of Intraparenchymally Infused Recombinant Methionyl Human Glial Cell Line-Derived Neurotrophic Factor for the Treatment of Progressive Supranuclear Palsy.? This protocol is being sponsored by the Division of Intramural Research (DIR), NINDS. Vanderbilt University Medical Center has a professional staff uniquely qualified by training and prior experience to satisfy the highly specialized demands of this protocol. The professional staff has, in particular, the expertise in functional and stereotactic neurosurgery for movement disorders which is vital to the success of this protocol. Vanderbilt has been involved in the execution of this project from the very outset of its initiation and has successfully performed neurosurgical installation of intracranial devices and their connecting systems and pumps as well as experience in administering the experimental drug under the protocol. Vanderbilt is considered the only source capable to continue and complete the remaining neurological implant requirements of the protocol. To do otherwise, would jeopardize the continuity of the study as well as the safety of the patients. A one-year contract, with up to four option years, utilizing up to ten patients during the five year period, beginning in September 2002, is anticipated. This organization, by virtue of their preliminary and current work under this protocol, is considered to be the only source that can reasonably provide the prerequisite knowledge, skilled personnel, surgical experience and expertise for performance of this proposed acquisition pursuant to 41 USC 253?(1) as set forth in FAR 6.302-1. The inherent duplication of cost and performance delays that would be incurred and associated with considering other sources are unacceptable to the Government. This is not a Request for Proposals (RFP). See Note 22*****
- Place of Performance
- Address: Nashville, TN
- Zip Code: 37232-2270
- Zip Code: 37232-2270
- Record
- SN00065341-W 20020426/020424213213 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |